Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2129

1.

Approach to ocular toxoplasmosis including pregnant women.

Cortés JA, Roncancio Á, Uribe LG, Cortés-Luna CF, Montoya JG.

Curr Opin Infect Dis. 2019 Jul 15. doi: 10.1097/QCO.0000000000000577. [Epub ahead of print]

PMID:
31313714
2.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387. [Epub ahead of print]

PMID:
31310323
3.

Genetics of Thyroid Disorders.

Cortés JMR, Zerón HM.

Folia Med (Plovdiv). 2019 Jun 1;61(2):172-179. doi: 10.2478/folmed-2018-0078. Review.

PMID:
31301652
4.

Catalyst Behavior in Metal-Catalyzed Carbonyl-Olefin Metathesis.

Hanson CS, Psaltakis MC, Cortes JJ, Devery Iii JJ.

J Am Chem Soc. 2019 Jul 5. doi: 10.1021/jacs.9b02613. [Epub ahead of print]

PMID:
31276383
5.

Philadelphia chromosome-negative acute leukemia in chronic myeloid leukemia.

Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S.

Am J Hematol. 2019 Jul 4. doi: 10.1002/ajh.25571. [Epub ahead of print] No abstract available.

PMID:
31273842
6.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
7.

Phylogeography and Population Genetics of Vicugna vicugna: Evolution in the Arid Andean High Plateau.

González BA, Vásquez JP, Gómez-Uchida D, Cortés J, Rivera R, Aravena N, Chero AM, Agapito AM, Varas V, Wheleer JC, Orozco-terWengel P, Marín JC.

Front Genet. 2019 Jun 6;10:445. doi: 10.3389/fgene.2019.00445. eCollection 2019.

8.

PTEN Activity Defines an Axis for Plasticity at Cortico-Amygdala Synapses and Influences Social Behavior.

Sánchez-Puelles C, Calleja-Felipe M, Ouro A, Bougamra G, Arroyo A, Diez I, Erramuzpe A, Cortés J, Martínez-Hernández J, Luján R, Navarrete M, Venero C, Chan A, Morales M, Esteban JA, Knafo S.

Cereb Cortex. 2019 Jun 26. pii: bhz103. doi: 10.1093/cercor/bhz103. [Epub ahead of print]

PMID:
31240311
9.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
10.

Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications.

Maurizi A, Capulli M, Curle A, Patel R, Ucci A, Côrtes JA, Oxford H, Lamandé SR, Bateman JF, Rucci N, Teti A.

Bone Res. 2019 Jun 11;7:17. doi: 10.1038/s41413-019-0055-x. eCollection 2019.

11.

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS.

Clin Lymphoma Myeloma Leuk. 2019 May 13. pii: S2152-2650(19)30147-8. doi: 10.1016/j.clml.2019.05.008. [Epub ahead of print]

12.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0512-y. [Epub ahead of print] Review.

PMID:
31209280
13.

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM.

Lancet Haematol. 2019 Jun 14. pii: S2352-3026(19)30087-0. doi: 10.1016/S2352-3026(19)30087-0. [Epub ahead of print]

PMID:
31208943
14.

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A.

Clin Transl Oncol. 2019 Jun 15. doi: 10.1007/s12094-019-02145-4. [Epub ahead of print]

PMID:
31203575
15.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
16.

Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources.

Forns J, Cainzos-Achirica M, Hellfritzsch M, Morros R, Poblador-Plou B, Hallas J, Giner-Soriano M, Prados-Torres A, Pottegård A, Cortés J, Castellsagué J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M.

Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):965-975. doi: 10.1002/pds.4803. Epub 2019 Jun 6.

PMID:
31172633
17.

Differential Poststroke Motor Recovery in an Arm Versus Hand Muscle in the Absence of Motor Evoked Potentials.

Schambra HM, Xu J, Branscheidt M, Lindquist M, Uddin J, Steiner L, Hertler B, Kim N, Berard J, Harran MD, Cortes JC, Kitago T, Luft A, Krakauer JW, Celnik PA.

Neurorehabil Neural Repair. 2019 Jul;33(7):568-580. doi: 10.1177/1545968319850138. Epub 2019 Jun 6.

PMID:
31170880
18.

Adherence to reporting guidelines increases the number of citations: the argument for including a methodologist in the editorial process and peer-review.

Vilaró M, Cortés J, Selva-O'Callaghan A, Urrutia A, Ribera JM, Cardellach F, Basagaña X, Elmore M, Vilardell M, Altman D, González JA, Cobo E.

BMC Med Res Methodol. 2019 May 31;19(1):112. doi: 10.1186/s12874-019-0746-4.

19.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 May 31. doi: 10.1002/cncr.32196. [Epub ahead of print]

PMID:
31150121
20.

Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial.

Abilleira S, Pérez de la Ossa N, Jiménez X, Cardona P, Cocho D, Purroy F, Serena J, Román LS, Urra X, Vilaró M, Cortés J, González JA, Chamorro Á, Gallofré M, Jovin T, Molina C, Cobo E, Dávalos A, Ribó M.

Int J Stroke. 2019 May 29:1747493019852176. doi: 10.1177/1747493019852176. [Epub ahead of print]

PMID:
31142219
21.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C.

Cell Rep. 2019 May 28;27(9):2690-2708.e10. doi: 10.1016/j.celrep.2019.04.098.

22.

Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases.

Murueta-Goyena A, Del Pino R, Reyero P, Galdós M, Arana B, Lucas-Jiménez O, Acera M, Tijero B, Ibarretxe-Bilbao N, Ojeda N, Peña J, Cortés J, Gómez-Esteban JC, Gabilondo I.

Mov Disord. 2019 May 28. doi: 10.1002/mds.27728. [Epub ahead of print]

PMID:
31136022
23.

Hedgehog signaling inhibitors in solid and hematological cancers.

Cortes JE, Gutzmer R, Kieran MW, Solomon JA.

Cancer Treat Rev. 2019 Jun;76:41-50. doi: 10.1016/j.ctrv.2019.04.005. Epub 2019 May 6. Review.

24.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.

Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H.

Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862. [Epub ahead of print]

PMID:
31125272
25.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
26.

The safety of eribulin for the treatment of metastatic breast cancer.

Perez-Garcia JM, Cortes J.

Expert Opin Drug Saf. 2019 May;18(5):347-355. doi: 10.1080/14740338.2019.1608946. Epub 2019 May 20. Review.

PMID:
31107111
27.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A.

Front Oncol. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. eCollection 2019.

28.

Prediction of Alzheimer's disease dementia with MRI beyond the short-term: Implications for the design of predictive models.

Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019 Apr 30;23:101837. doi: 10.1016/j.nicl.2019.101837. [Epub ahead of print]

29.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA.

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960.

30.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J.

Future Oncol. 2019 May 10. doi: 10.2217/fon-2019-0180. [Epub ahead of print]

31.

[Laparoscopic renal cyst excision: Large simple renal cyst treatment with renal cell carcinoma cells in its wall. Histogenetic considerations and bibliographic review.]

Serrano Á, Sánchez M, Ciappara M, López E, Laso S, Jerez T, Barrera J, Cortés JA, González-Peramato P, Blazquez J, Moreno J.

Arch Esp Urol. 2019 May;72(4):422-428. Spanish.

PMID:
31070139
32.

Fluidal pyroclasts reveal the intensity of peralkaline rhyolite pumice cone eruptions.

Clarke B, Calder ES, Dessalegn F, Fontijn K, Cortés JA, Naylor M, Butler I, Hutchison W, Yirgu G.

Nat Commun. 2019 May 1;10(1):2010. doi: 10.1038/s41467-019-09947-8.

33.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
34.

Carbohydrate Self-Assembly at Surfaces: STM Imaging of Sucrose Conformation and Ordering on Cu(100).

Abb S, Tarrat N, Cortés J, Andriyevsky B, Harnau L, Schön JC, Rauschenbach S, Kern K.

Angew Chem Int Ed Engl. 2019 Jun 17;58(25):8336-8340. doi: 10.1002/anie.201901340. Epub 2019 May 24.

PMID:
31018027
35.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
36.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
37.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.

38.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.

PMID:
30977385
39.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
40.

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.

Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B.

Curr Med Res Opin. 2019 Apr 9:1-8. doi: 10.1080/03007995.2019.1605239. [Epub ahead of print]

PMID:
30964361
41.

The antifungal activity and mechanisms of action of quantified extracts from berries, leaves and roots of Phytolacca tetramera.

Butassi E, Svetaz LA, Zhou S, Wolfender JL, Cortés JCG, Ribas JC, Díaz C, Palacio JP, Vicente F, Zacchino SA.

Phytomedicine. 2019 Mar 16:152884. doi: 10.1016/j.phymed.2019.152884. [Epub ahead of print]

PMID:
30922815
42.

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.

Berdeja JG, Heinrich MC, Dakhil SR, Goldberg SL, Wadleigh M, Kuriakose P, Cortes J, Radich J, Helton B, Rizzieri D, Paley C, Dautaj I, Mauro MJ.

Leuk Lymphoma. 2019 Mar 26:1-10. doi: 10.1080/10428194.2019.1590569. [Epub ahead of print]

PMID:
30912699
43.

Investigating the Formation of Structural Elements in Proteins Using Local Sequence-Dependent Information and a Heuristic Search Algorithm.

Estaña A, Ghallab M, Bernadó P, Cortés J.

Molecules. 2019 Mar 22;24(6). pii: E1150. doi: 10.3390/molecules24061150.

44.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE.

Blood Adv. 2019 Mar 26;3(6):851-861. doi: 10.1182/bloodadvances.2018025874.

45.

Textural and geochemical constraints on andesitic plug emplacement prior to the 2004-2010 vulcanian explosions at Galeras volcano, Colombia.

Bain AA, Calder ES, Cortés JA, Cortés GP, Loughlin SC.

Bull Volcanol. 2019;81(1):1. doi: 10.1007/s00445-018-1260-y. Epub 2018 Dec 7.

46.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.

Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ.

Am J Hematol. 2019 Jun;94(6):E158-E160. doi: 10.1002/ajh.25454. Epub 2019 Mar 18. No abstract available.

PMID:
30838674
47.

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations.

Ramos J, Vega JF, Cruz V, Sanchez-Sanchez E, Cortes J, Martinez-Salazar J.

Int J Mol Sci. 2019 Mar 1;20(5). pii: E1076. doi: 10.3390/ijms20051076.

48.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE.

Int J Hematol. 2019 May;109(5):545-552. doi: 10.1007/s12185-019-02620-2. Epub 2019 Mar 4.

PMID:
30830579
49.

Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.

Pladevall-Vila M, Pottegård A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hägg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortés J, Aguado J, Perlemuter G, Falissard B, Castellsagué J, Jacquot E, Deltour N, Perez-Gutthann S.

CNS Drugs. 2019 Apr;33(4):383-395. doi: 10.1007/s40263-019-00611-9.

50.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597

Supplemental Content

Loading ...
Support Center